Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations

REFERENCES

1. 1.↵
   1. Konduri S,
   2. Singh M,
   3. Bobustuc G,
   4. Rovin R,
   5. Kassam A

   . Epidemiology of male breast cancer. Breast. 2020;54:8-14. doi: 10.1016/j.breast.2020.08.010

   OpenUrlCrossRef
2. 2.↵
   1. Li X,
   2. Yang J,
   3. Krishnamurti U,
   4. et al.

   Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer. 2017;17(5):356-366. doi: 10.1016/j.clbc.2017.03.005

   OpenUrlCrossRef
3. 3.↵
   1. Seal S,
   2. Thompson D,
   3. Renwick A,
   4. et al.

   Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239-1241. doi: 10.1038/ng1902

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Johnston SRD,
   2. Harbeck N,
   3. Hegg R,
   4. et al.

   Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. doi: 10.1200/JCO.20.02514

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Adam MP,
   2. Feldman J,
   3. Mirzaa GM

   1. Petrucelli N,
   2. Daly MB,
   3. Pal T

   . BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, , Feldman J, , Mirzaa GM, et al., eds. GeneReviews [Internet]. University of Washington, Seattle. 1993-2023. Published September 4, 1996. Updated September 21, 2023. Accessed December 17, 2023. ncbi.nlm.nih.gov/books/NBK1247/
6. 6.↵
   1. Tai YC,
   2. Domchek S,
   3. Parmigiani G,
   4. Chen S

   . Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811-1814. doi: 10.1093/jnci/djm203

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Ibrahim M,
   2. Yadav S,
   3. Ogunleye F,
   4. Zakalik D

   . Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18(1):179. doi: 10.1186/s12885-018-4098-y

   OpenUrlCrossRef
8. 8.↵
   1. Fostira F,
   2. Saloustros E,
   3. Apostolou P,
   4. et al.

   Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Res Treat. 2018;169(1):105-113. doi: 10.1007/s10549-018-4661-x

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Katheeja MN,
   2. Das SP,
   3. Das R,
   4. Laha S

   . BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity. Front Genet. 2023;14:1035052. doi: 10.3389/fgene.2023.1035052

   OpenUrlCrossRef
10. 10.↵
    1. Muhseena N K,
    2. Mathukkada S,
    3. Das SP,
    4. Laha S

    . The repair gene BACH1—a potential oncogene. Oncol Rev. 2021;15(1):519. doi: 10.4081/oncol.2021.519

    OpenUrlCrossRef
11. 11.↵
    1. Weber-Lassalle N,
    2. Hauke J,
    3. Ramser J,
    4. et al.

    BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res. 2018;20(1):7. doi: 10.1186/s13058-018-0935-9

    OpenUrlCrossRefPubMed
12. 12.
    1. Rafnar T,
    2. Gudbjartsson DF,
    3. Sulem P,
    4. et al.

    Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104-1107. doi: 10.1038/ng.955

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Song H,
    2. Ramus SJ,
    3. Kjaer SK,
    4. et al.

    Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One. 2007;2(3):e268. doi: 10.1371/journal.pone.0000268

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Hassett MJ,
    2. Somerfield MR,
    3. Giordano SH

    . Management of male breast cancer: ASCO guideline summary. JCO Oncol Pract. 2020;16(8):e839-e843. doi: 10.1200/JOP.19.00792

    OpenUrlCrossRef
15. 15.↵
    1. Giordano SH

    . A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471-479. doi: 10.1634/theoncologist.10-7-471

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Giordano SH,
    2. Cohen DS,
    3. Buzdar AU,
    4. Perkins G,
    5. Hortobagyi GN

    . Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51-57. doi: 10.1002/cncr.20312

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Leone J,
    2. Zwenger AO,
    3. Leone BA,
    4. Vallejo CT,
    5. Leone JP

    . Overall survival of men and women with breast cancer according to tumor subtype: a population-based study. Am J Clin Oncol. 2019;42(2):215-220. doi: 10.1097/COC.0000000000000497

    OpenUrlCrossRef